Galectin Therapeutics Q2 FY26 net loss widens 21.17% to $9.11 million - GALT News | RalliesGalectin Therapeutics Q2 FY26 net loss widens 21.17% to $9.11 million
G
GALT• Q2 FY26 results
- Galectin Therapeutics posted a GAAP net loss of USD 9.11 million, widening from USD 7.52 million a year earlier.
- Loss per share widened to USD 0.14 from USD 0.12, while operating loss narrowed to USD 3.98 million from USD 4.63 million.
- Research and development expense fell 34% to USD 2.14 million, while general and administrative costs rose 35% to USD 1.85 million.
- Cash and cash equivalents declined to USD 13.27 million from USD 17.72 million at Dec. 31, 2025.
Regulatory and funding update
- FDA Type C meeting set a regulatory path; Phase 3 protocol filing targeted for Q3 2026, with funding and partnership discussions ongoing.
DIOD
•
